N/A
N=7,749
Patient Activation After DXA Result Notification
Osteoporosis · Bone Diseases, Metabolic
Bottom Line
View on ClinicalTrials.gov: NCT01507662 ↗Enrolled (actual)
7,749
Serious AEs
—
Results posted
Apr 2017
Primary outcome: Primary: Guideline Concordant Osteoporosis Therapy — 2537; 2477 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Bone Mineral Density Result Letter and Bone Health Brochure (Behavioral)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Fredric D Wolinsky
- Primary completion
- Nov 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Guideline Concordant Osteoporosis Therapy |
2537; 2477 | — |
Summary
There is growing evidence that patients undergoing bone mineral density testing (BMD) often do not take important steps to improve their bone health. The investigators will conduct a randomized-controlled trial to evaluate the impact of a novel and practical patient activation intervention (mailing patients their bone density test results) on the quality of bone-related healthcare and the cost-effectiveness of BMD testing. Equally important, the investigators intervention could easily be modified to include other patient populations and chronic diseases.
Eligibility Criteria
Inclusion Criteria
- patients presenting for DXA
- age 50 years of age or older
Exclusion Criteria
- non-English speakers
- prisoners
- people who have mental disabilities
- individuals younger than age 50 years
- individuals who do not have access to a telephone
- deaf patients
Data sourced from ClinicalTrials.gov (NCT01507662). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.